Before we malign the CC, why don't we wait until t
Post# of 148169
I have read the PRs and watched the proactive videos, which lead me to believe that Cytodyn has, in fact, applied for EUA for Leronlimab to the FDA and the equivalent of EUA to MHRA.
Cytodyn and FDA have also been in communication to address the issues raised in the RTF.
Cytodyn has also been in communication with NASDAQ to achieve uplisting. As has been discussed repeatedly, NASDAQ was not able to act until 10-K complete, which does not occur overnight.
Those are the steps the company in taking to get EUA/Approval and NASDAQ uplisting.
These certainly seem to be concrete steps. Do you have a suggestion for a better path? My knowledge of the FDA and NASDAQ regulatory processes is incomplete, but the actions of Cytodyn nonetheless seem appropriate and progressing to the desired ends.